AU2022369135A1 - Topical compositions and methods for photodynamic therapy - Google Patents

Topical compositions and methods for photodynamic therapy Download PDF

Info

Publication number
AU2022369135A1
AU2022369135A1 AU2022369135A AU2022369135A AU2022369135A1 AU 2022369135 A1 AU2022369135 A1 AU 2022369135A1 AU 2022369135 A AU2022369135 A AU 2022369135A AU 2022369135 A AU2022369135 A AU 2022369135A AU 2022369135 A1 AU2022369135 A1 AU 2022369135A1
Authority
AU
Australia
Prior art keywords
composition
skin
topical composition
amount
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022369135A
Other languages
English (en)
Inventor
Haydar ABDALGHAFOR
Brenden B. HADJIKEZIAN
Tasnuva HAQUE
Xiaopin Jin
Scott Lundahl
Pradeep Sanghvi
Jerzy Zadykowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Sun Pharmaceutical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Inc filed Critical Sun Pharmaceutical Industries Inc
Publication of AU2022369135A1 publication Critical patent/AU2022369135A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022369135A 2021-10-19 2022-10-19 Topical compositions and methods for photodynamic therapy Pending AU2022369135A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257175P 2021-10-19 2021-10-19
US63/257,175 2021-10-19
PCT/IB2022/060058 WO2023067519A1 (en) 2021-10-19 2022-10-19 Topical compositions and methods for photodynamic therapy

Publications (1)

Publication Number Publication Date
AU2022369135A1 true AU2022369135A1 (en) 2024-05-09

Family

ID=84245894

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022369135A Pending AU2022369135A1 (en) 2021-10-19 2022-10-19 Topical compositions and methods for photodynamic therapy

Country Status (7)

Country Link
US (2) US20230131170A1 (https=)
EP (1) EP4419074A1 (https=)
JP (1) JP2024542943A (https=)
AU (1) AU2022369135A1 (https=)
CA (1) CA3235710A1 (https=)
IL (1) IL312286A (https=)
WO (1) WO2023067519A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860807T3 (es) 2015-10-15 2021-10-05 Dusa Pharmaceuticals Inc Iluminador ajustable para terapia y diagnóstico fotodinámicos
US10357567B1 (en) 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
JP2025537694A (ja) * 2022-11-04 2025-11-20 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 光線力学的療法の方法
WO2025046471A1 (en) * 2023-08-28 2025-03-06 Sun Pharmaceutical Industries, Inc. Photodynamic therapy in combination with an hedgehog pathway inhibitor for use in treating non-melanoma skin cancer
WO2025235557A2 (en) 2024-05-07 2025-11-13 Sun Pharmaceutical Industries, Inc. Photodynamic therapy illuminator and photodynamic therapy methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5954703A (en) 1997-10-31 1999-09-21 Dusa Pharmaceuticals, Inc. Method and apparatus for applying 5-aminolevulinic acid
US6223071B1 (en) 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
EP3143986A1 (en) * 2015-09-21 2017-03-22 Zimmer MedizinSysteme GmbH Hydrophilic gel for topical delivery of 5-aminolevulinic acid and production thereof
ES2860807T3 (es) 2015-10-15 2021-10-05 Dusa Pharmaceuticals Inc Iluminador ajustable para terapia y diagnóstico fotodinámicos
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
US10814114B2 (en) 2015-12-08 2020-10-27 Dusa Pharmaceuticals, Inc. Method and apparatus for applying a topical solution
US10357567B1 (en) * 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy

Also Published As

Publication number Publication date
US20230131170A1 (en) 2023-04-27
IL312286A (en) 2024-06-01
CA3235710A1 (en) 2023-04-27
US20250009884A1 (en) 2025-01-09
WO2023067519A1 (en) 2023-04-27
EP4419074A1 (en) 2024-08-28
JP2024542943A (ja) 2024-11-19

Similar Documents

Publication Publication Date Title
US20250009884A1 (en) Topical compositions and methods for photodynamic therapy
Morton et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications–actinic keratoses, Bowen's disease and basal cell carcinomas
JP7734222B2 (ja) 皮膚障害に対する光線力学的治療方法
KR101717792B1 (ko) 히알루론산, 글루코사민 또는 알란토인을 포함하는 산화성의 광활성화된 피부 회춘용 조성물
RU2444385C2 (ru) Способ фотодинамической терапии для лечения целлюлитов и косметического использования
Yu et al. Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion
US20060093561A1 (en) Method of treating microorganisms in the oral cavity
EP1819360A1 (en) Method of treating microorganisms in the oral cavity via photodynamic therapy employing a non-coherent light source
JP2017503785A (ja) 座瘡のパルス光力学的処置
US20100255080A1 (en) Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
Yang et al. Topical methotrexate pretreatment enhances the therapeutic effect of topical 5-aminolevulinic acid-mediated photodynamic therapy on hamster buccal pouch precancers
De Bruijn et al. Fractionated illumination after topical application of 5-aminolevulinic acid on normal skin of hairless mice: the influence of the dark interval
KR102047193B1 (ko) 글루타밀아미도에틸인돌을 활성 성분으로 포함하는 피부 트러블 개선용 외용제 조성물 및 광역학적 치료 조성물
Gu et al. Light-emitting diodes for healthcare and well-being
RU2827761C1 (ru) Способ лечения воспалительных заболеваний слизистой оболочки полости рта и тканей пародонта методом фотодинамической терапии с применением фотосенсибилизатора на основе липосом с куркумином
MX2015000429A (es) Composiciones farmaceuticas para el suministro topico de fotosesibilizadores y usos de los mismos.
US20230035733A1 (en) Management of dermal neurofibromatosis lesions
RU2395315C1 (ru) Способ фотодинамической терапии гнойных ран и трофических язв
De Vijlder et al. Fractionated PDT with 5-aminolevulinic acid: effective, cost effective, and patient friendly
de Haas et al. Fractionated illumination significantly improves the reponse of superficial basal cell carcinoma to ALA-PDT
HK1225610B (zh) 包含透明质酸、葡糖胺或尿囊素的氧化光活化皮肤再生组合物